{"doc_id": "si-2022-0211-reg-1", "parent_doc_id": "si-2022-0211", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "1. This Order may be cited as the Misuse of Drugs Act 1977 (Controlled", "text_raw": "1. This Order may be cited as the Misuse of Drugs Act 1977 (Controlled \n\nDrugs) (Designation) Order 2022. \n\nIn this Order, “Act” means the Misuse of Drugs Act 1977 (No. 12 of", "text_norm": "1 order may cited misuse drug act 1977 (controlled drugs) (designation) order 2022 order act mean misuse drug act 1977 (no 12", "start_char": 1150, "end_char": 1327, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-2", "parent_doc_id": "si-2022-0211", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": null, "text_raw": "2. \n1977).", "text_norm": "2 1977)", "start_char": 1327, "end_char": 1340, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-3", "parent_doc_id": "si-2022-0211", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "3. The following are revoked:", "text_raw": "3. The following are revoked: \n\n(a) \n\n(b) \n\n(c) \n\nthe Misuse of Drugs (Controlled Drugs) (Designation) \n(Amendment) Order 2017 (S.I. No. 533 of 2017); \n\nthe Misuse of Drugs (Controlled Drugs) (Designation) \n(Amendment) Order 2019 (S.I. No. 281 of 2019); and \n\nthe Misuse of Drugs (Controlled Drugs) (Designation) Order \n2021 (S.I. No. 122 of 2021).", "text_norm": "3 following revoked (a) (b) (c) misuse drug (controlled drugs) (designation) (amendment) order 2017 (s.i no 533 2017) misuse drug (controlled drugs) (designation) (amendment) order 2019 (s.i no 281 2019) misuse drug (controlled drugs) (designation) order 2021 (s.i no 122 2021)", "start_char": 1340, "end_char": 1691, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-4", "parent_doc_id": "si-2022-0211", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "4. The drugs specified in Schedule 1 are designated as drugs to which", "text_raw": "4. The drugs specified in Schedule 1 are designated as drugs to which \n\nsubsection (1) of section 13 of the Act applies.", "text_norm": "4 drug specified schedule 1 designated drug subsection (1) section 13 act applies", "start_char": 1691, "end_char": 1814, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-5", "parent_doc_id": "si-2022-0211", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "5. The purposes set out in Schedule 2 are specified for the purposes of", "text_raw": "5. The purposes set out in Schedule 2 are specified for the purposes of \n\nsubsection (1)(a) of section 13 of the Act. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 3rd May, 2022. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[211] 3 \n\nRegulation 4 \n\nDrugs designated as drugs to which section 13(1) of the Act applies", "text_norm": "5 purpose set schedule 2 specified purpose subsection (1)(a) section 13 act notice making statutory instrument published iris oifigiuil 3rd may 2022 211 3 regulation 4 drug designated drug section 13(1) act applies", "start_char": 1814, "end_char": 2159, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-schedule-1", "parent_doc_id": "si-2022-0211", "section_id": "schedule-1", "section_label": "SCHEDULE 1", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": null, "text_raw": "SCHEDULE 1", "text_norm": "schedule 1", "start_char": 2159, "end_char": 2172, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-1", "parent_doc_id": "si-2022-0211", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "(a) The following substances and products, namely-", "text_raw": "1. \n\n(a) The following substances and products, namely- \n\nN-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3carboxamide (otherwise known as Clockwork Orange, 5F \nAKB48) \n\nN-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2yl]-1-\n(cyclohexylmethyl)-1H-indazole-3-carboxamide (otherwise \nknown as ADB-CHMINACA) \n\nN-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)1H-indazole-3-carboxamide (otherwise known as ADBFUBINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-\n(cyclohexylmethyl)-1H-indazole-3-carboxamide (otherwise \nknown as AB-CHMINACA) \n\n(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)1H-indazole-3-carboxamide (otherwise known as ABFUBINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-pentyl-1Hindazole-3-carboxamide (otherwise known as AB-PINACA) \n\n5-(2-Aminopropyl)indole (otherwise known as 5-IT) \n\n1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone \n\nN-(1-Benzyl-4-piperidyl)propionanilide \n\n2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25BNBOMe) \n\n1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine \n(otherwise known as BromodragonFLY) \n\nBufotenine \n\nCannabinol, except where contained in Cannabis or cannabis \nresin \n\nCannabinol derivatives, not being dronabinol or its stereoisomers \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [211] \n\nCannabis (not being a preparation specified in paragraph 5 of Part \n1 of Schedule 4 of the Misuse of Drugs Regulations 2017 (S.I. \nNo. 173 of 2017) or a preparation or product specified in \nSchedule 1 to the Misuse of Drugs (Prescription and Control of \nSupply of cannabis for Medical Use) Regulations 2019 (S.I. No. \n262 of 2019)) and permitted for supply pursuant to those \nRegulations \n\nCannabis resin \n\nCathinone \n\n2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25CNBOMe) \n\n1-(4-Cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3carboxamide (otherwise known as CUMYL-4CN-BINACA) \n\n1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (otherwise known \nas MT-45) \n\nCoca leaf \n\nConcentrate of poppy straw \n\n3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl] \nbenzamide (otherwise known as AH-7921) \n\n3,4-Dichloro-N-(2-dimethylamino-cyclohexyl)-N-methylbenzamide (otherwise known as U-47700) \n\n[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone \n\nN,N-Diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1Hbenzo[d]imidazol-1-yl)ethan-1-amine (otherwise known as \nIsotonitazene) \n\nN,N-Diethyltryptamine \n\n2,5-Dimethoxy-α,4-dimethylphenethylamine \n\nN,N-Dimethyltryptamine \n\n3-Dimethylheptyl-11-hydroxyhexahydrocannabinol \n\n1-(1,2-Diphenylethyl)piperidine (otherwise known as \nDiphenidine) \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[211] 5 \n\nEthyl phenyl(piperidin-2-yl)acetate (otherwise known as \nEthylphenidate) \n\nEticyclidine \n\nEtryptamine \n\n[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3tetramethylcyclopropyl)methanone (otherwise known as XLR-11) \n\n1-(2-Fluorophenyl)-2-methylaminopropan-1-one \n\n1-(3-Fluorophenyl)-2-methylaminopropan-1-one \n\n1-(4-Fluorophenyl)-2-methylaminopropan-1-one \n\n9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol \n\n[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate \n\nN-Hydroxy-tenamphetamine \n\n2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25INBOMe) \n\nKhat (being the leaves of Catha edulis (Celastraceae)) \n\nLysergamide \n\nLysergide and other N-alkyl derivatives of lysergamide \n\nMescaline \n\nMethcathinone \n\n1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine (otherwise known \nas 3-Methoxyphencyclidine) \n\n2-(3-Methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise \nknown as methoxetamine) \n\n1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one \n\nMethyl (2S,4aR,6aR,7R,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1Hbenzo[f]isochromene-7-carboxylate (otherwise known as \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [211] \n\nSalvinorin A) and any product, whether natural or otherwise, \nincluding any plant or plant material of any kind or description, \nwhich contains any proportion of the said substance \n\n2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one \n\n2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one \n\n4-Methyl-aminorex \n\nMethyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3dimethylbutanoate (otherwise known as MDMB CHMICA) \n\nMethyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3carboxamido)butanoate (otherwise known as MDMB-4enPINACA) \n\nMethyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy2,3,4,6,7,12b-hexahydro-1H-indolo[2,3a]quinolizin-2-yl]-3methoxyprop-2-enoate (otherwise known as 7Hydroxymitragynine) and any product, whether natural or \notherwise, including any plant or plant material of any kind or \ndescription, which contains any proportion of the said substance \n\nMethyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy1,2,3,4,6,7,12,12b-octahydroindolo[2,3a]quinolizin-2-yl]-3methoxyprop-2-enoate (otherwise known as Mitragynine) and any \nproduct, whether natural or otherwise, including any plant or \nplant material of any kind or description, which contains any \nproportion of the said substance \n\nMethyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate (otherwise known 4F-MDMB-BINACA) \n\nMethyl 2-({[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}amino)3,3-dimethylbutanoate (otherwise known as 4F-MDMB-BICA) \n\nMethyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3carbonyl]amino}-3,3-dimethylbutanoate (otherwise known as 5FMDMB-PINACA) \n\nMethyl (1-(5-fluoropentyl)-1H-indazole-3-carbonyl)valinate \n(otherwise known as 5F-AMB-PINACA) \n\nMethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3dimethylbutanoate (otherwise known as 5F-MDMB-PICA) \n\nMethyl (2S)-2[[1-[(4-fluorophenyl)methyl]indazole-3carbonyl]amino]-3-methylbutanoate (otherwise known as FUBAMB) \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[211] 7 \n\n4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine \n(otherwise known as 4,4’-DMAR) \n\nα-Methyl-4-(methylthio)phenethylamine \n\n1-(4-Methylphenyl)-2-methylaminopropan-1-one \n\n(1-Pentyl-1H-indol-3-yl)(2,2,3,3tetramethylcyclopropyl)methanone (otherwise known as UR-144) \n\n5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3b]indol-1-one (otherwise known as CUMYL-PEGACLONE) \n\nN-Methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known as \nMethiopropamine) \n\nPsilocin \n\nQuinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate \n(otherwise known as Clockwork Orange, PB22) \n\nRaw opium \n\nRolicyclidine \n\nTenocyclidine \n\nN-[1-(2-Thenyl)-4-piperidyl]propionanilide \n\n(b) Any substance (not being bupropion, diethylpropion or \n\npyrovalerone) structurally derived from 2-amino-1-phenyl-1propanone by modification in any of the following ways: \n\n(i) \n\nby substitution in the phenyl ring to any extent with alkyl, \nalkenyl, alkynyl, alkoxy, alkylthio, alkylenedioxy, haloalkyl \nor halo substituents, whether or not further substituted in the \nphenyl ring by one or more other univalent substituents; \n\n(ii) by substitution at the 2- or 3-position of the propanone side-\n\nchain with an alkyl substituent; \n\n(iii) \n\n by substitution at the nitrogen atom with one or more alkyl \nor dialkyl groups, or by inclusion of the nitrogen atom in a \ncyclic structure. \n\n(c) Any substance structurally derived from 2-amino-1-propanone by \nsubstitution at the 1-position with any monocyclic, or fusedpolycyclic ring system (not being a phenyl ring or \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f8 [211] \n\nalkylenedioxyphenyl ring system), whether or not the substance is \nfurther modified in any of the following ways: \n\n(i) \n\nby substitution in the ring system to any extent with alkyl, \nalkenyl, alkynyl, alkoxy, alkylthio, haloalkyl or halo \nsubstituents, whether or not further substituted in the ring \nsystem by one or more other univalent substituents; \n\n(ii) by substitution at the 3-position with an alkyl substituent; \n\n(iii) by substitution at the 2-amino nitrogen atom with one or \n\nmore alkyl or dialkyl groups, or by inclusion of the 2-amino \nnitrogen atom in a cyclic structure. \n\n(d) Any substance structurally derived from 3-(1-benzoyl)indole or 3-\n(1-naphthoyl)indole by modification in any of the following \nways: \n\n(i) \n\nby substitution at the nitrogen atom of the indole ring by \nalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4morpholinyl)ethyl; \n\n(ii) by replacement of one or more hydrogen atoms of any of \nthe substituents referred to in clause (i), with a halo \nsubstituent; \n\nwhether or not further substituted in the indole ring to any extent \nand whether or not substituted in the phenyl or naphthyl ring to \nany extent. \n\n(e) 1-Benzylpiperazine or any substance (not being a substance \nspecified in Schedule 3) structurally derived from 1benzylpiperazine or 1-phenylpiperazine by modification in any of \nthe following ways: \n\n(i) \n\nby substitution at the second nitrogen atom of the piperazine \nring with alkyl, benzyl, haloalkyl or phenyl groups; \n\n(ii) by substitution in the aromatic ring to any extent with alkyl, \n\nalkoxy, alkylenedioxy, halo or haloalkyl groups. \n\n(f) Any substance (not being a substance specified in Schedule 2) \n\nstructurally derived from fentanyl by modification in one or more \nof the following ways, that is to say: \n\n(i) \n\nby replacement of the phenyl portion of the phenethyl group \nby any heteromonocycle whether or not further substituted \nin the heterocycle; \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[211] 9 \n\n(ii) by substitution in the phenethyl group with alkyl, alkenyl, \n\nalkoxy, hydroxy, halo, haloalkyl, amino or nitro groups; \n\n(iii) by substitution in the piperidine ring with alkyl or alkenyl \n\ngroups; \n\n(iv) by substitution in the aniline ring with alkyl, alkoxy, \n\nalkylenedioxy, halo or haloalkyl groups; \n\n(v) by substitution at the 4-position of the piperidine ring with \nany alkoxycarbonyl or alkoxyalkyl or acyloxy group; \n\n(vi) by replacement of the N-propionyl group by another acyl \n\ngroup. \n\n(g) Any substance structurally derived from 2-(3-\n\nhydroxycyclohexyl)phenol by substitution at the 5-position of the \nphenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl \nor 2-(4-morpholinyl)ethyl, whether or not further substituted in \nthe cyclohexyl ring to any extent. \n\n(h) Any substance structurally derived from 3-(1-naphthoyl)indole or \n1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen \natom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, \ncycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further \nsubstituted in the indole ring to any extent and whether or not \nsubstituted in the naphthyl ring to any extent. \n\n(i) Any substance structurally derived from 3-(1-naphthoyl)pyrrole \nby substitution at the nitrogen atom of the pyrrole ring by alkyl, \nalkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4morpholinyl)ethyl, whether or not further substituted in the \npyrrole ring to any extent and whether or not substituted in the \nnaphthyl ring to any extent. \n\n(j) Any substance structurally derived from 1-(1-\n\nnaphthylmethyl)indene by substitution at the 3-position of the \nindene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl \nor 2-(4-morpholinyl)ethyl, whether or not further substituted in \nthe indene ring to any extent and whether or not substituted in the \nnaphthyl ring to any extent. \n\n(k) Any substance (not being a substance specified in Schedule 2) \n\nstructurally derived from pethidine by modification in one or \nmore of the following ways, that is to say: \n\n(i) \n\nby replacement of the 1-methyl group by an acyl, alkyl \n(whether or not unsaturated), benzyl or phenethyl group, \nwhether or not further substituted; \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f10 [211] \n\n(ii) by substitution in the piperidine ring with alkyl or alkenyl \n\ngroups or with a propano bridge, whether or not further \nsubstituted; \n\n(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, \n\naryloxy, halo or haloalkyl groups; \n\n(iv) by replacement of the 4-ethoxycarbonyl by any other \nalkoxycarbonyl or any alkoxyalkyl or acyloxy group; \n\n(v) by formation of an N-oxide or of a quaternary base. \n\n(l) Any substance (not being methoxyphenamine) structurally \n\nderived from phenethylamine, an N-alkyl-phenethylamine, αmethylphenethylamine, an N-alkyl- α-methylphenethylamine, αethylphenethylamine, or an N-alkyl-α-ethylphenethylamine by \nsubstitution in the ring to any extent with alkyl, alkoxy, \nalkylenedioxy or halo substituents, whether or not further \nsubstituted in the ring by one or more other univalent substituents. \n\n(m) \n\n Any substance structurally derived from 3-phenylacetylindole by \nsubstitution at the nitrogen atom of the indole ring with alkyl, \nalkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4morpholinyl)ethyl, whether or not further substituted in the indole \nring to any extent and whether or not substituted in the phenyl \nring to any extent. \n\n(n) Any fungus containing any proportion of Psilocin or of an ester of \n\nPsilocin. \n\n(o) 1,2,3,4-Tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2amine or 2,3-dihydro-1H-inden-2-amine or any substance \nstructurally derived from 1,2,3,4-tetrahydronaphthalen-2-amine, \n1,2-dihydronaphthalen-2-amine or 2,3-dihydro-1H-inden-2-amine \nby modification in any of the following ways: \n\n(i) \n\nby substitution in the phenyl ring to any extent with alkyl, \nalkoxy, alkenyl, alkynyl, alkylthio, alkylenedioxy, \nhaloalkyl, hydroxy or halo substituents, whether or not \nfurther substituted by one or more other univalent \nsubstituents; \n\n(ii) by mono- or di-substitution at the nitrogen atom with alkyl, \nalkenyl, alkynyl or haloalkyl groups or by inclusion of the \nnitrogen atom in a cyclic structure. \n\n(p) Any substance structurally derived from tryptamine or from a \n\nring-hydroxy tryptamine by substitution at the nitrogen atom of \nthe side-chain with one or more alkyl substituents but no other \nsubstituent. \n\n \n \n \n \n \n \n \n \n \n \n \n\f[211] 11", "text_norm": "1 (a) following substance product namely- n-(adamantan-1-yl)-1-(5-fluoropentyl)-1h-indazole-3carboxamide (otherwise known clockwork orange 5f akb48) n- (2s)-1-amino-3 3-dimethyl-1-oxobutan-2yl -1- (cyclohexylmethyl)-1h-indazole-3-carboxamide (otherwise known adb-chminaca) n-(1-amino-3 3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)1h-indazole-3-carboxamide (otherwise known adbfubinaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2-yl -1- (cyclohexylmethyl)-1h-indazole-3-carboxamide (otherwise known ab-chminaca) (s)-n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)1h-indazole-3-carboxamide (otherwise known abfubinaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2yl -1-pentyl-1hindazole-3-carboxamide (otherwise known ab-pinaca) 5-(2-aminopropyl)indole (otherwise known 5-it) 1-(1 3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone n-(1-benzyl-4-piperidyl)propionanilide 2-(4-bromo-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25bnbome) 1-(4-bromofuro 2 3-f 1 benzofuran-8-yl)propan-2-amine (otherwise known bromodragonfly) bufotenine cannabinol except contained cannabis cannabis resin cannabinol derivative dronabinol stereoisomers 4 211 cannabis (not preparation specified paragraph 5 part 1 schedule 4 misuse drug regulation 2017 (s.i no 173 2017) preparation product specified schedule 1 misuse drug (prescription control supply cannabis medical use) regulation 2019 (s.i no 262 2019)) permitted supply pursuant regulation cannabis resin cathinone 2-(4-chloro-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25cnbome) 1-(4-cyanobutyl)-n-(1-methyl-1-phenylethyl)-1h-indazole-3carboxamide (otherwise known cumyl-4cn-binaca) 1-cyclohexyl-4-(1 2-diphenylethyl)piperazine (otherwise known mt-45) coca leaf concentrate poppy straw 3 4-dichloro-n- 1-(dimethylamino)cyclohexyl methyl benzamide (otherwise known ah-7921) 3 4-dichloro-n-(2-dimethylamino-cyclohexyl)-n-methylbenzamide (otherwise known u-47700) 2 3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo 1 2 3de -1 4-benzoxazin-6-yl -1-naphthalenylmethanone n n-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1hbenzo imidazol-1-yl)ethan-1-amine (otherwise known isotonitazene) n n-diethyltryptamine 2 5-dimethoxy-a 4-dimethylphenethylamine n n-dimethyltryptamine 3-dimethylheptyl-11-hydroxyhexahydrocannabinol 1-(1 2-diphenylethyl)piperidine (otherwise known diphenidine) 211 5 ethyl phenyl(piperidin-2-yl)acetate (otherwise known ethylphenidate) eticyclidine etryptamine 1-(5-fluoropentyl)-1h-indol-3-yl (2 2 3 3tetramethylcyclopropyl)methanone (otherwise known xlr-11) 1-(2-fluorophenyl)-2-methylaminopropan-1-one 1-(3-fluorophenyl)-2-methylaminopropan-1-one 1-(4-fluorophenyl)-2-methylaminopropan-1-one 9-(hydroxymethyl)-6 6-dimethyl-3-(2-methyloctan-2-yl)6a 7 10 10a-tetrahydrobenzo c chromen-1-ol 9-hydroxy-6-methyl-3- 5-phenylpentan-2-yl oxy5 6 6a 7 8 9 10 10a-octahydrophenanthridin-1-yl acetate n-hydroxy-tenamphetamine 2-(4-iodo-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25inbome) khat (being leaf catha edulis (celastraceae)) lysergamide lysergide n-alkyl derivative lysergamide mescaline methcathinone 1-(1-(3-methoxyphenyl)cyclohexyl)piperidine (otherwise known 3-methoxyphencyclidine) 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise known methoxetamine) 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one methyl (2s 4ar 6ar 7r 10as 10br)-9-acetyloxy-2-(furan-3-yl)6a 10b-dimethyl-4 10-dioxo-2 4a 5 6 7 8 9 10a-octahydro-1hbenzo f isochromene-7-carboxylate (otherwise known 6 211 salvinorin a) product whether natural otherwise including plant plant material kind description contains proportion said substance 2-methylamino-1-(3 4-methylenedioxyphenyl)butan-1-one 2-methylamino-1-(3 4-methylenedioxyphenyl)propan-1-one 4-methyl-aminorex methyl 2- 1-(cyclohexylmethyl)indole-3-carbonyl amino -3 3dimethylbutanoate (otherwise known mdmb chmica) methyl 3 3-dimethyl-2-(1-(pent-4-en-1-yl)-1h-indazole-3carboxamido)butanoate (otherwise known mdmb-4enpinaca) methyl (e)-2- (2s 3 7as 12bs)-3-ethyl-7a-hydroxy-8-methoxy2 3 4 6 7 12b-hexahydro-1h-indolo 2 3a quinolizin-2-yl -3methoxyprop-2-enoate (otherwise known 7hydroxymitragynine) product whether natural otherwise including plant plant material kind description contains proportion said substance methyl (e)-2- (2s 3 12bs)-3-ethyl-8-methoxy1 2 3 4 6 7 12 12b-octahydroindolo 2 3a quinolizin-2-yl -3methoxyprop-2-enoate (otherwise known mitragynine) product whether natural otherwise including plant plant material kind description contains proportion said substance methyl 2-(1-(4-fluorobutyl)-1h-indazole-3-carboxamido)-3 3dimethylbutanoate (otherwise known 4f-mdmb-binaca) methyl 2-( 1-(4-fluorobutyl)-1h-indol-3-yl carbonyl amino)3 3-dimethylbutanoate (otherwise known 4f-mdmb-bica) methyl (2s)-2- 1-(5-fluoropentyl)-1h-indazole-3carbonyl amino -3 3-dimethylbutanoate (otherwise known 5fmdmb-pinaca) methyl (1-(5-fluoropentyl)-1h-indazole-3-carbonyl)valinate (otherwise known 5f-amb-pinaca) methyl 2-(1-(5-fluoropentyl)-1h-indole-3-carboxamido)-3 3dimethylbutanoate (otherwise known 5f-mdmb-pica) methyl (2s)-2 1- (4-fluorophenyl)methyl indazole-3carbonyl amino -3-methylbutanoate (otherwise known fubamb) 211 7 4-methyl-5-(4-methylphenyl)-4 5-dihydro-1 3-oxazol-2-amine (otherwise known 4 4 -dmar) a-methyl-4-(methylthio)phenethylamine 1-(4-methylphenyl)-2-methylaminopropan-1-one (1-pentyl-1h-indol-3-yl)(2 2 3 3tetramethylcyclopropyl)methanone (otherwise known ur-144) 5-pentyl-2-(2-phenylpropan-2-yl)-2 5-dihydro-1h-pyrido 4 3b indol-1-one (otherwise known cumyl-pegaclone) n-methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known methiopropamine) psilocin quinolin-8-yl 1-(5-fluoropentyl)-1h-indole-3-carboxylate (otherwise known clockwork orange pb22) raw opium rolicyclidine tenocyclidine n- 1-(2-thenyl)-4-piperidyl propionanilide (b) substance (not bupropion diethylpropion pyrovalerone) structurally derived 2-amino-1-phenyl-1propanone modification following way (i) substitution phenyl ring extent alkyl alkenyl alkynyl alkoxy alkylthio alkylenedioxy haloalkyl halo substituents whether substituted phenyl ring one univalent substituents (ii) substitution 2- 3-position propanone side- chain alkyl substituent (iii) substitution nitrogen atom one alkyl dialkyl group inclusion nitrogen atom cyclic structure (c) substance structurally derived 2-amino-1-propanone substitution 1-position monocyclic fusedpolycyclic ring system (not phenyl ring 8 211 alkylenedioxyphenyl ring system) whether substance modified following way (i) substitution ring system extent alkyl alkenyl alkynyl alkoxy alkylthio haloalkyl halo substituents whether substituted ring system one univalent substituents (ii) substitution 3-position alkyl substituent (iii) substitution 2-amino nitrogen atom one alkyl dialkyl group inclusion 2-amino nitrogen atom cyclic structure (d) substance structurally derived 3-(1-benzoyl)indole 3- (1-naphthoyl)indole modification following way (i) substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4morpholinyl)ethyl (ii) replacement one hydrogen atom substituents referred clause (i) halo substituent whether substituted indole ring extent whether substituted phenyl naphthyl ring extent (e) 1-benzylpiperazine substance (not substance specified schedule 3) structurally derived 1benzylpiperazine 1-phenylpiperazine modification following way (i) substitution second nitrogen atom piperazine ring alkyl benzyl haloalkyl phenyl group (ii) substitution aromatic ring extent alkyl alkoxy alkylenedioxy halo haloalkyl group (f) substance (not substance specified schedule 2) structurally derived fentanyl modification one following way say (i) replacement phenyl portion phenethyl group heteromonocycle whether substituted heterocycle 211 9 (ii) substitution phenethyl group alkyl alkenyl alkoxy hydroxy halo haloalkyl amino nitro group (iii) substitution piperidine ring alkyl alkenyl group (iv) substitution aniline ring alkyl alkoxy alkylenedioxy halo haloalkyl group (v) substitution 4-position piperidine ring alkoxycarbonyl alkoxyalkyl acyloxy group (vi) replacement n-propionyl group another acyl group (g) substance structurally derived 2-(3- hydroxycyclohexyl)phenol substitution 5-position phenolic ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted cyclohexyl ring extent (h) substance structurally derived 3-(1-naphthoyl)indole 1h-indol-3-yl-(1-naphthyl)methane substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indole ring extent whether substituted naphthyl ring extent (i) substance structurally derived 3-(1-naphthoyl)pyrrole substitution nitrogen atom pyrrole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4morpholinyl)ethyl whether substituted pyrrole ring extent whether substituted naphthyl ring extent (j) substance structurally derived 1-(1- naphthylmethyl)indene substitution 3-position indene ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indene ring extent whether substituted naphthyl ring extent (k) substance (not substance specified schedule 2) structurally derived pethidine modification one following way say (i) replacement 1-methyl group acyl alkyl (whether unsaturated) benzyl phenethyl group whether substituted 10 211 (ii) substitution piperidine ring alkyl alkenyl group propano bridge whether substituted (iii) substitution 4-phenyl ring alkyl alkoxy aryloxy halo haloalkyl group (iv) replacement 4-ethoxycarbonyl alkoxycarbonyl alkoxyalkyl acyloxy group (v) formation n-oxide quaternary base (l) substance (not methoxyphenamine) structurally derived phenethylamine n-alkyl-phenethylamine amethylphenethylamine n-alkyl- a-methylphenethylamine aethylphenethylamine n-alkyl-a-ethylphenethylamine substitution ring extent alkyl alkoxy alkylenedioxy halo substituents whether substituted ring one univalent substituents (m) substance structurally derived 3-phenylacetylindole substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4morpholinyl)ethyl whether substituted indole ring extent whether substituted phenyl ring extent (n) fungus containing proportion psilocin ester psilocin (o) 1 2 3 4-tetrahydronaphthalen-2-amine 1 2-dihydronaphthalen-2amine 2 3-dihydro-1h-inden-2-amine substance structurally derived 1 2 3 4-tetrahydronaphthalen-2-amine 1 2-dihydronaphthalen-2-amine 2 3-dihydro-1h-inden-2-amine modification following way (i) substitution phenyl ring extent alkyl alkoxy alkenyl alkynyl alkylthio alkylenedioxy haloalkyl hydroxy halo substituents whether substituted one univalent substituents (ii) mono- di-substitution nitrogen atom alkyl alkenyl alkynyl haloalkyl group inclusion nitrogen atom cyclic structure (p) substance structurally derived tryptamine ring-hydroxy tryptamine substitution nitrogen atom side-chain one alkyl substituents substituent 211 11", "start_char": 2172, "end_char": 16139, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-2", "parent_doc_id": "si-2022-0211", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "2. Any stereoisomeric form of a substance specified in paragraph 1.", "text_raw": "2. Any stereoisomeric form of a substance specified in paragraph 1.", "text_norm": "2 stereoisomeric form substance specified paragraph 1", "start_char": 16139, "end_char": 16209, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-3", "parent_doc_id": "si-2022-0211", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "3. Any ester or ether of a substance specified in paragraph 1 or 2.", "text_raw": "3. Any ester or ether of a substance specified in paragraph 1 or 2.", "text_norm": "3 ester ether substance specified paragraph 1 2", "start_char": 16209, "end_char": 16279, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-4", "parent_doc_id": "si-2022-0211", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.", "text_raw": "4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.", "text_norm": "4 salt substance specified paragraph 1 2 3", "start_char": 16279, "end_char": 16350, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-reg-5", "parent_doc_id": "si-2022-0211", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "5. Any preparation or other product containing any proportion of a", "text_raw": "5. Any preparation or other product containing any proportion of a \n\nsubstance or product specified in any of paragraphs 1, 2, 3 or 4, not \nbeing a preparation specified in Schedule 5 of the Misuse of Drugs \nRegulations 2017 (S.I. No. 173 of 2017). \n\n \n \n \n \n \n \n \n \n \n\f12 [211] \n\nRegulation 5 \n\nPurposes specified for the purposes of section 13(1)(a) of the Act", "text_norm": "5 preparation product containing proportion substance product specified paragraph 1 2 3 4 preparation specified schedule 5 misuse drug regulation 2017 (s.i no 173 2017) 12 211 regulation 5 purpose specified purpose section 13(1)(a) act", "start_char": 16350, "end_char": 16715, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-schedule-2", "parent_doc_id": "si-2022-0211", "section_id": "schedule-2", "section_label": "SCHEDULE 2", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "The following purposes, namely:-", "text_raw": "SCHEDULE 2 \n\nThe following purposes, namely:- \n\n(a) research, forensic analysis or use as an essential intermediate or starting \n\nmaterial in an industrial manufacturing process; \n\n(b) the growing of hemp from seed varieties specified, by the Commission \nof the European Communities, as being eligible for the purposes of \nArticle 1 of Regulation (EU) No. 1307/2013 of the European Parliament \nand of the Council of 17 December 20131; \n\nsubject to such licensing provision under the Act and the Regulations made \nthereunder as are applicable. \n\nGIVEN under my Official Seal, \n\n27 April, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n1 OJ No. L 347, 20.12.2013, p. 608. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[211] 13", "text_norm": "schedule 2 following purpose namely - (a) research forensic analysis use essential intermediate starting material industrial manufacturing process (b) growing hemp seed variety specified commission european community eligible purpose article 1 regulation (eu) no 1307 2013 european parliament council 17 december 20131 subject licensing provision act regulation made thereunder applicable given official seal 27 april 2022 stephen donnelly minister health 1 oj no l 347 20.12.2013 p 608 211 13", "start_char": 16715, "end_char": 17440, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
{"doc_id": "si-2022-0211-explanatory-note", "parent_doc_id": "si-2022-0211", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 211 of 2022", "title": "specified in Schedule 1, any of the things mentioned in subsection", "year": 2022, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation). \n\nThe purpose of this Order is to replace the Misuse of Drugs (Designation) Order \n2021 (S.I. No. 122 of 2021), thereby adding the following to the list of drugs to \nwhich section 13(1) of the Misuse of Drugs Act 1977 applies: \n\n(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (otherwise known as AB-FUBINACA) \n\nN,N-Diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol1-yl)ethan-1-amine (otherwise known as Isotonitazene) \n\n1-(1,2-Diphenylethyl)piperidine (otherwise known as Diphenidine) \n\n1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine (otherwise known as 3Methoxyphencyclidine) \n\nMethyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3carboxamido)butanoate (otherwise known as MDMB-4en-PINACA) \n\nMethyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate (otherwise known 4F-MDMB-BINACA) \n\nMethyl 2-({[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}amino)-3,3dimethylbutanoate (otherwise known as 4F-MDMB-BICA) \n\nMethyl (1-(5-fluoropentyl)-1H-indazole-3-carbonyl)valinate (otherwise \nknown as 5F-AMB-PINACA) \n\nMethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3dimethylbutanoate (otherwise known as 5F-MDMB-PICA) \n\n5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol1-one (otherwise known as CUMYL-PEGACLONE) \n\nThis Order may be cited as the Misuse of Drugs Act 1977 (Controlled Drugs) \n(Designation) Order 2022. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f14 [211] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.50 \n\n(DH-371) 75. 5/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation) purpose order replace misuse drug (designation) order 2021 (s.i no 122 2021) thereby adding following list drug section 13(1) misuse drug act 1977 applies (s)-n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1hindazole-3-carboxamide (otherwise known ab-fubinaca) n n-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1h-benzo imidazol1-yl)ethan-1-amine (otherwise known isotonitazene) 1-(1 2-diphenylethyl)piperidine (otherwise known diphenidine) 1-(1-(3-methoxyphenyl)cyclohexyl)piperidine (otherwise known 3methoxyphencyclidine) methyl 3 3-dimethyl-2-(1-(pent-4-en-1-yl)-1h-indazole-3carboxamido)butanoate (otherwise known mdmb-4en-pinaca) methyl 2-(1-(4-fluorobutyl)-1h-indazole-3-carboxamido)-3 3dimethylbutanoate (otherwise known 4f-mdmb-binaca) methyl 2-( 1-(4-fluorobutyl)-1h-indol-3-yl carbonyl amino)-3 3dimethylbutanoate (otherwise known 4f-mdmb-bica) methyl (1-(5-fluoropentyl)-1h-indazole-3-carbonyl)valinate (otherwise known 5f-amb-pinaca) methyl 2-(1-(5-fluoropentyl)-1h-indole-3-carboxamido)-3 3dimethylbutanoate (otherwise known 5f-mdmb-pica) 5-pentyl-2-(2-phenylpropan-2-yl)-2 5-dihydro-1h-pyrido 4 3-b indol1-one (otherwise known cumyl-pegaclone) order may cited misuse drug act 1977 (controlled drugs) (designation) order 2022 14 211 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.50 (dh-371) 75 5 22 propylon", "start_char": 17440, "end_char": 19474, "source_path": "downloads\\2022\\2022_0210.pdf", "extraction_method": "pdfminer", "checksum": "sha256:7f31eb6961e3768ea0b2aeb7e8d50654e879b7425558bd25beb5d15b1c796f5b", "cross_refs": []}
